Pharsight

Drugs that contain Atogepant

1. Qulipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 17, 2026
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

NCE-1 date: 2025-09-28

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

QULIPTA family patents

Family Patents